View Future GrowthDT Cloud Star Acquisition 과거 순이익 실적과거 기준 점검 2/6DT Cloud Star Acquisition의 연간 평균 수익은 80.8%였으며, Capital Markets 산업의 수익은 연간 6.3% 증가했습니다.핵심 정보80.81%순이익 성장률70.34%주당순이익(EPS) 성장률Capital Markets 산업 성장률10.26%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 12DT Cloud Star Acquisition Corp Receives Notice of Non-Compliance with Nasdaq Listing Rule 5450(a)(2)On April 6, 2026, DT Cloud Star Acquisition Corporation (the Company) received a letter (the Deficiency Letter) from the Listing Qualifications Staff of The Nasdaq Stock Market (Nasdaq) indicating that based on a shareholder range analysis provided by the Company to Nasdaq dated March 27, 2026, the Company is not in compliance with Listing Rule 5450(a)(2) (the Minimum Public Holders Rule), which requires the Company to maintain at least 400 total holders for continued listing on The Nasdaq Global Market. The Deficiency Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Deficiency Letter states that the Company has 45 calendar days, or until May 21, 2026, to submit a plan to regain compliance with Listing Rule 5450(a)(2). If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance with Listing Rule 5450(a)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the Capital Market). The Company is exploring all options to regain compliance with Listing Rule 5450(a)(2) and intends to submit a plan to regain compliance within the required timeframe. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.공시 • Feb 05Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction.Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction on February 2, 2026. A cash consideration of $1.5 billion will be paid by Primegen Us, Inc. As part of consideration, $1.5 billion is paid towards common equity of DT Cloud Star Acquisition Corporation. The combined company is expected to operate as PrimeGen US. PrimeGen US is anticipated to list on the Nasdaq, subject to Nasdaq approval, under a new ticker symbol. The transaction is subject to subject to antitrust regulations, minimum balance sheet requirements, approval by regulatory board, approval of offer by acquirer shareholders and approval of offer by target shareholders. The transaction is currently expected to close in the second half of 2026. A.G.P. / Alliance Global Partners, LLC acted as financial advisor for Primegen Us, Inc. Sichenzia Ross Ference Carmel LLP acted as legal advisor for Primegen Us, Inc. Loeb & Loeb LLP acted as legal advisor for DT Cloud Star Acquisition Corporation. Steven C. Schinko of Schinko Law acted as legal advisor for Primegen Us, Inc.공시 • Jan 23DT Cloud Star Acquisition Corporation Receives A Deficiency Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn January 15, 2026, DT Cloud Star Acquisition Corporation received a letter (the “Deficiency Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on its Market Value of Listed Securities (“MVLS”) for the period from November 21, 2025 to January 6, 2026, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(b)(2)(A), to maintain a minimum MVLS of $50,0000,000. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until July 14, 2026, in which to regain compliance with Nasdaq continued listing requirement. Nasdaq will provide written confirmation of compliance to the Company and close this matter if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days during this compliance period. In the event the Company does not regain compliance prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting, in which situation the Company may appeal the delisting determination to a Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the “Capital Market”). The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(b)(2)(A), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.공시 • Nov 29DT Cloud Star Acquisition Corporation Appoints Xunyong Zhou as DirectorOn November 26, 2025, the board of directors of DT Cloud Star Acquisition Corporation (the “Company”) appointed Dr. Xunyong Zhou as a director of the Company. Dr. Zhou, aged 50, is an entrepreneur and researcher with over 6 years of experience in biotechnology and health innovation. Dr. Zhou’s main topic of research is enzyme-based theory for food products, cosmetics, daily chemicals and tea, and he holds over 20 patents as of now. Dr. Zhou is a pioneering figure in biotechnology and digital health innovation. He has served as director for Huakang Biomedical Holdings Company Limited since November 2025. Since January 2023, He has been leading advancements in biological enzyme solutions and cell therapy technologies through Nanjing Hezhen Holding Group Co. Ltd., where he serves as chairman and integrates healthcare generative pre-training transformer and enzyme therapy expertise to co-create a collaborative platform offering next-generation health solutions. Dr. Zhou also oversees Changsha Kerong Health Technology Co. Ltd., which has built a multidisciplinary health service team comprising medical, product, and service experts centered on delivering AI-enhanced health education, health consultation, and health management services. From March 2019 to January 2023, Dr. Zhou took the role of chairman for Zhenzhen Suqian Biotechnology Co. Ltd. Dr. Zhou graduated from Tianjin University of the PRC with a bachelor degree of engineering majoring in business administration in 2002 and Fudan University of the PRC with a master degree of laws in 2011. Dr. Zhou subsequently obtained his doctorate degree in business administration from the Université Nice Sophia Antipolis in Nice, France in 2016. He is currently the honorary chairman of the Vaccine and Immune Health Branch of the Liaoning Immunology Society and a member of the National Enzyme Engineering and Fermentation Engineering Professional Committee.공시 • Sep 12DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025, at 10:00 China Standard Time. Location: offices of loeb & loeb llp, 2206-19, 1 connaught pl, central, Hong Kong공시 • Apr 16Dt Cloud Star Acquisition Corporation Announces Chief Executive Officer Changes, Effective April 14, 2025DT Cloud Star Acquisition Corporation announced that effective April 14, 2025, Bian Fan was removed as Chief Executive Officer of DT Cloud Star Acquisition Corporation by the written consent of the board of directors of the Company. On the same date, to fill the vacancy, the Board appointed Sam Zheng Sun as the Chief Executive Officer of the Company. Mr. Sun was a managing director of the private equity investment department of Affinity Equity Partners, a Hong Kong-headquartered firm that focuses on private equity investments across South Korea, Australia and New Zealand, Greater China and Southeast Asia between March 2021 and February 2023. Prior to that, Mr. Sun was a partner at Sequoia Capital based in Beijing, where he focused on private equity investments, between October 2018 and April 2020. Mr. Sun obtained his MBA degree from UCLA Anderson School of Management in 2007 and Bachelor’s degree in computer science and economics from University of Pittsburgh in 1997.매출 및 비용 세부 내역DT Cloud Star Acquisition가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGM:DTSQ 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 26011031 Dec 25021030 Sep 25030030 Jun 25030031 Mar 25020031 Dec 24010030 Sep 24000030 Jun 24000031 Mar 24000031 Dec 230000양질의 수익: DTSQ는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 지난 1년 동안 DTSQ의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: DTSQ의 수익은 지난 5년 동안 연평균 80.8%로 크게 증가했습니다.성장 가속화: DTSQ은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: DTSQ은 지난 1년 동안 수익이 감소(-24.1%)하여 Capital Markets 업계 평균(38.3%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: DTSQ의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/14 18:40종가2026/06/11 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스DT Cloud Star Acquisition Corporation는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 12DT Cloud Star Acquisition Corp Receives Notice of Non-Compliance with Nasdaq Listing Rule 5450(a)(2)On April 6, 2026, DT Cloud Star Acquisition Corporation (the Company) received a letter (the Deficiency Letter) from the Listing Qualifications Staff of The Nasdaq Stock Market (Nasdaq) indicating that based on a shareholder range analysis provided by the Company to Nasdaq dated March 27, 2026, the Company is not in compliance with Listing Rule 5450(a)(2) (the Minimum Public Holders Rule), which requires the Company to maintain at least 400 total holders for continued listing on The Nasdaq Global Market. The Deficiency Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Deficiency Letter states that the Company has 45 calendar days, or until May 21, 2026, to submit a plan to regain compliance with Listing Rule 5450(a)(2). If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance with Listing Rule 5450(a)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the Capital Market). The Company is exploring all options to regain compliance with Listing Rule 5450(a)(2) and intends to submit a plan to regain compliance within the required timeframe. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.
공시 • Feb 05Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction.Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction on February 2, 2026. A cash consideration of $1.5 billion will be paid by Primegen Us, Inc. As part of consideration, $1.5 billion is paid towards common equity of DT Cloud Star Acquisition Corporation. The combined company is expected to operate as PrimeGen US. PrimeGen US is anticipated to list on the Nasdaq, subject to Nasdaq approval, under a new ticker symbol. The transaction is subject to subject to antitrust regulations, minimum balance sheet requirements, approval by regulatory board, approval of offer by acquirer shareholders and approval of offer by target shareholders. The transaction is currently expected to close in the second half of 2026. A.G.P. / Alliance Global Partners, LLC acted as financial advisor for Primegen Us, Inc. Sichenzia Ross Ference Carmel LLP acted as legal advisor for Primegen Us, Inc. Loeb & Loeb LLP acted as legal advisor for DT Cloud Star Acquisition Corporation. Steven C. Schinko of Schinko Law acted as legal advisor for Primegen Us, Inc.
공시 • Jan 23DT Cloud Star Acquisition Corporation Receives A Deficiency Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn January 15, 2026, DT Cloud Star Acquisition Corporation received a letter (the “Deficiency Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on its Market Value of Listed Securities (“MVLS”) for the period from November 21, 2025 to January 6, 2026, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(b)(2)(A), to maintain a minimum MVLS of $50,0000,000. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until July 14, 2026, in which to regain compliance with Nasdaq continued listing requirement. Nasdaq will provide written confirmation of compliance to the Company and close this matter if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days during this compliance period. In the event the Company does not regain compliance prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting, in which situation the Company may appeal the delisting determination to a Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the “Capital Market”). The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(b)(2)(A), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
공시 • Nov 29DT Cloud Star Acquisition Corporation Appoints Xunyong Zhou as DirectorOn November 26, 2025, the board of directors of DT Cloud Star Acquisition Corporation (the “Company”) appointed Dr. Xunyong Zhou as a director of the Company. Dr. Zhou, aged 50, is an entrepreneur and researcher with over 6 years of experience in biotechnology and health innovation. Dr. Zhou’s main topic of research is enzyme-based theory for food products, cosmetics, daily chemicals and tea, and he holds over 20 patents as of now. Dr. Zhou is a pioneering figure in biotechnology and digital health innovation. He has served as director for Huakang Biomedical Holdings Company Limited since November 2025. Since January 2023, He has been leading advancements in biological enzyme solutions and cell therapy technologies through Nanjing Hezhen Holding Group Co. Ltd., where he serves as chairman and integrates healthcare generative pre-training transformer and enzyme therapy expertise to co-create a collaborative platform offering next-generation health solutions. Dr. Zhou also oversees Changsha Kerong Health Technology Co. Ltd., which has built a multidisciplinary health service team comprising medical, product, and service experts centered on delivering AI-enhanced health education, health consultation, and health management services. From March 2019 to January 2023, Dr. Zhou took the role of chairman for Zhenzhen Suqian Biotechnology Co. Ltd. Dr. Zhou graduated from Tianjin University of the PRC with a bachelor degree of engineering majoring in business administration in 2002 and Fudan University of the PRC with a master degree of laws in 2011. Dr. Zhou subsequently obtained his doctorate degree in business administration from the Université Nice Sophia Antipolis in Nice, France in 2016. He is currently the honorary chairman of the Vaccine and Immune Health Branch of the Liaoning Immunology Society and a member of the National Enzyme Engineering and Fermentation Engineering Professional Committee.
공시 • Sep 12DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025, at 10:00 China Standard Time. Location: offices of loeb & loeb llp, 2206-19, 1 connaught pl, central, Hong Kong
공시 • Apr 16Dt Cloud Star Acquisition Corporation Announces Chief Executive Officer Changes, Effective April 14, 2025DT Cloud Star Acquisition Corporation announced that effective April 14, 2025, Bian Fan was removed as Chief Executive Officer of DT Cloud Star Acquisition Corporation by the written consent of the board of directors of the Company. On the same date, to fill the vacancy, the Board appointed Sam Zheng Sun as the Chief Executive Officer of the Company. Mr. Sun was a managing director of the private equity investment department of Affinity Equity Partners, a Hong Kong-headquartered firm that focuses on private equity investments across South Korea, Australia and New Zealand, Greater China and Southeast Asia between March 2021 and February 2023. Prior to that, Mr. Sun was a partner at Sequoia Capital based in Beijing, where he focused on private equity investments, between October 2018 and April 2020. Mr. Sun obtained his MBA degree from UCLA Anderson School of Management in 2007 and Bachelor’s degree in computer science and economics from University of Pittsburgh in 1997.